JP2023514426A5 - - Google Patents

Info

Publication number
JP2023514426A5
JP2023514426A5 JP2022550755A JP2022550755A JP2023514426A5 JP 2023514426 A5 JP2023514426 A5 JP 2023514426A5 JP 2022550755 A JP2022550755 A JP 2022550755A JP 2022550755 A JP2022550755 A JP 2022550755A JP 2023514426 A5 JP2023514426 A5 JP 2023514426A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
aminolevulinic acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022550755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514426A (ja
JP7719787B2 (ja
Filing date
Publication date
Priority claimed from EP20158341.6A external-priority patent/EP3868372A1/en
Application filed filed Critical
Publication of JP2023514426A publication Critical patent/JP2023514426A/ja
Publication of JP2023514426A5 publication Critical patent/JP2023514426A5/ja
Application granted granted Critical
Publication of JP7719787B2 publication Critical patent/JP7719787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022550755A 2020-02-19 2021-02-18 アルテミシニン化合物、５－アミノレブリン酸またはメチル－５－アミノレブリン酸、および化学療法剤の医薬配合物 Active JP7719787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20158341.6A EP3868372A1 (en) 2020-02-19 2020-02-19 A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
EP20158341.6 2020-02-19
PCT/EP2021/054039 WO2021165405A1 (en) 2020-02-19 2021-02-18 A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent

Publications (3)

Publication Number Publication Date
JP2023514426A JP2023514426A (ja) 2023-04-05
JP2023514426A5 true JP2023514426A5 (https=) 2024-02-26
JP7719787B2 JP7719787B2 (ja) 2025-08-06

Family

ID=69779738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550755A Active JP7719787B2 (ja) 2020-02-19 2021-02-18 アルテミシニン化合物、５－アミノレブリン酸またはメチル－５－アミノレブリン酸、および化学療法剤の医薬配合物

Country Status (15)

Country Link
US (1) US20230121771A1 (https=)
EP (2) EP3868372A1 (https=)
JP (1) JP7719787B2 (https=)
KR (1) KR20220143097A (https=)
CN (1) CN114786661A (https=)
AU (1) AU2021222339A1 (https=)
BR (1) BR112022014692A2 (https=)
CA (1) CA3165208A1 (https=)
DK (1) DK3989961T3 (https=)
ES (1) ES2972799T3 (https=)
FI (1) FI3989961T3 (https=)
IL (1) IL294856A (https=)
PL (1) PL3989961T3 (https=)
PT (1) PT3989961T (https=)
WO (1) WO2021165405A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184234A1 (en) * 2020-11-30 2022-06-16 Sonalasense, Inc. Metabolic targeting of low grade tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225148B1 (en) 1995-03-10 2006-07-28 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
TWI482621B (zh) * 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
JP2011225471A (ja) * 2010-04-16 2011-11-10 Univ Of Tsukuba 抗癌剤の効果増強剤
US10925963B2 (en) * 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor
CN105963244A (zh) * 2016-01-15 2016-09-28 赵鸣 注射用青蒿琥酯制剂及其应用
CN106527586B (zh) * 2016-11-04 2019-09-06 吉林省北方医药有限责任公司 一种移动终端设备
CN108570089B (zh) * 2017-04-28 2019-10-29 云白药征武科技(上海)有限公司 双氢青蒿素-甾体结合物及其制备方法和应用
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
CN108635581A (zh) * 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用

Similar Documents

Publication Publication Date Title
US20150111869A1 (en) Use of a combination of a mek inhibitor and an erk inhibitor for treatment of hyperproliferative diseases
US20170232017A1 (en) Treatment of cancer
JP2021523169A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
JP2021513965A5 (https=)
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
JP2009536956A (ja) 抗癌治療法
JP2023514426A5 (https=)
US20130101680A1 (en) Radiotherapy enhancer
US20120093917A1 (en) Metnase and intnase inhibitors and their use in treating cancer
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
US6822001B2 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
JP2011514355A5 (https=)
EP2826482A1 (en) Novel antitumor agent comprising combination of three agents
JP6458007B2 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
US20220395575A1 (en) Combination therapy with protein kinase b activation inhibitor to treat cancer
CN103054871A (zh) 抗肿瘤效果增强剂、抗肿瘤剂和癌治疗方法
US11179349B2 (en) Use of tumor gene methylation regulator and anti-tumor drugs
US20250289806A1 (en) Compounds for proliferative disorders
CN100372535C (zh) 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
HK40121791A (zh) 利用mta协作的prmt5抑制剂的癌症治疗
CN115581703A (zh) 复方吉西他滨组合物及应用
JP2015199678A (ja) ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
HK40081068A (en) Miv-818/lenvatinib combination therapy for liver cancer